Lisanti Capital Growth’s Halozyme HALO Stock Holding History

Lisanti Capital Growth’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54,445	Closed	-$3.52M	–	127
2026 Q1	$3.52M	Buy	+54,445	New	+$3.84M	0.89%	51
2023 Q1	–	Sell	-147,320	Closed	-$8.38M	–	128
2022 Q4	$8.38M	Buy	+147,320	New	+$7.54M	1.14%	32
2022 Q3	–	Sell	-350,935	Closed	-$15.4M	–	121
2022 Q2	$15.4M	Buy	+350,935	New	+$15.2M	2.1%	9
2021 Q2	–	Sell	-263,460	Closed	-$11M	–	140
2021 Q1	$11M	Buy	+263,460	New	+$12M	1.41%	17
2016 Q1	–	Sell	-29,963	Closed	-$519K	–	102
2015 Q4	$519K	Buy	+29,963	New	+$478K	0.55%	74
2014 Q1	–	Sell	-29,315	Closed	-$439K	–	112
2013 Q4	$439K	Buy	+29,315	New	+$377K	0.18%	104

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Lisanti Capital Growth's HALO Position: Q2 2026 in Review

Lisanti Capital Growth sold out of Halozyme (HALO) in Q2 2026, closing a stake of 54,445 shares — an estimated $3.52M sold.

Lisanti Capital Growth first reported a position in HALO in Q4 2013 and held it in 6 quarters. The position peaked at $15.4M in Q2 2022. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

Lisanti Capital Growth reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
Lisanti Capital Growth sold 54,445 Halozyme shares in Q2 2026, an estimated $3.52M.
Lisanti Capital Growth first reported a position in Halozyme in Q4 2013 and held it in 6 quarters.
Lisanti Capital Growth's Halozyme position peaked at $15.4M in Q2 2022.
672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.